CRT 2017: ACS & AMI Management - STEMI 2017 Hot Topic: Multivessel Disease Treatment

Conference

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$14.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Overview

ACS & AMI Management - STEMI 2017 Hot Topic: Multivessel Disease Treatment

Featuring

Michael Lipinski
Barry Rutherford
Timothy Henry
Gregg Stone
George Dangas
Pieter Smits
Paul Gurbel
Dominick Angiolillo
Eric Bates

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$14.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Moment Components

Case Introduction: A STEMI Patient with Multivessel Disease - Michael Lipinski

Culprit Only Versus Multivessel Intervention in STEMI: A Word of Caution - Barry Rutherford

Culprit Only Versus Multivessel Intervention in STEMI: Treat Them All! - Timothy Henry

Should Cangrelor Be Used in Most STEMI Patients? - Gregg Stone

Optimal Anticoagulation for Patients With STEMI Bivalirudin Versus Heparin: What Should Be the Standard of Care in 2017? - George Dangas

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease? - Pieter Smits

With Ticagrelor and Crushing, Cangrelor Has Only a Niche Role - Paul Gurbel

What Should Be the Optimal Duration of DAPT in Patients With STEMI? - Dominick Angiolillo

When and How Should We Use Lytics in STEMI? - Eric Bates

Target Audience

Cardiologists
Interventional Cardiologists
Interventional Fellows
Interventional Radiologists
Vascular Surgeons
Emergency Physicians
Physicians with an interest in Cardiovascular Innovations

Learning Objectives

Loading Simple Education